Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890148417> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2890148417 endingPage "TPS2613" @default.
- W2890148417 startingPage "TPS2613" @default.
- W2890148417 abstract "TPS2613 Background: Toca 511 (vocimagene amiretrorepvec) is an investigational, conditionally lytic, retroviral replicating vector that selectively infects cancer cells. Toca 511 spreads through tumors, stably delivering an optimized cytosine deaminase (CD) gene that converts the prodrug, Toca FC (investigational, extended-release 5-FC), into 5-FU within the tumor microenvironment. Preclinical studies show 5-FU kills infected dividing cancer cells and diffuses and kills surrounding cancer cells, myeloid derived suppressor cells, and tumor associated macrophages, thus reestablishing tumor immunity. A prior clinical study showed CD protein expression in resected high grade glioma tumors after intravenous (IV) Toca 511 (1Cloughesy T, Walbert T, Bota D, et al. Neuro Oncol 2016; 18(suppl 6):vi17). In animal models of metastatic colorectal cancer, IV Toca 511 infected metastases; subsequent 5-FC treatment resulted in decreased tumor size, improved survival, and durable antitumor immunity (2Yagiz K, Rodriguez-Aguirre ME, Espinoza FL, et al. Molecular Therapy: Oncolytics. 2018; 8:14-26). Methods: Toca 6 is a Phase 1b, multicenter, open-label study (NCT02576665) investigating changes in immune activity after treatment with Toca 511 & Toca FC in patients with advanced solid tumors or lymphoma. Toca 511 is injected IV daily for 3 days, then intratumorally following biopsy or, for patients with brain metastases, into resection cavity walls following resection. Oral Toca FC is started ~4 weeks later and repeated every 4-6 weeks. Changes from baseline in intratumoral immune activity (infiltrating T-cell subpopulations, B cells, monocytes) at 4 weeks after start of Toca FC are assessed. Peripheral blood is analyzed for effector, memory, Treg, and myeloid lineage cells. Viral RNA, DNA, and CD protein expression in tumor after IV Toca 511 are measured. Safety and efficacy are assessed. Approximately 30 patients will be enrolled at 4 sites in the United States. Enrollment progress by tumor type will be provided at the time of the meeting. Clinical trial information: NCT02576665." @default.
- W2890148417 created "2018-09-27" @default.
- W2890148417 creator A5026742889 @default.
- W2890148417 creator A5032439439 @default.
- W2890148417 creator A5043628378 @default.
- W2890148417 creator A5046981381 @default.
- W2890148417 creator A5069777765 @default.
- W2890148417 creator A5071750897 @default.
- W2890148417 creator A5073281082 @default.
- W2890148417 creator A5078163062 @default.
- W2890148417 date "2018-05-20" @default.
- W2890148417 modified "2023-09-25" @default.
- W2890148417 title "Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma." @default.
- W2890148417 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps2613" @default.
- W2890148417 hasPublicationYear "2018" @default.
- W2890148417 type Work @default.
- W2890148417 sameAs 2890148417 @default.
- W2890148417 citedByCount "0" @default.
- W2890148417 crossrefType "journal-article" @default.
- W2890148417 hasAuthorship W2890148417A5026742889 @default.
- W2890148417 hasAuthorship W2890148417A5032439439 @default.
- W2890148417 hasAuthorship W2890148417A5043628378 @default.
- W2890148417 hasAuthorship W2890148417A5046981381 @default.
- W2890148417 hasAuthorship W2890148417A5069777765 @default.
- W2890148417 hasAuthorship W2890148417A5071750897 @default.
- W2890148417 hasAuthorship W2890148417A5073281082 @default.
- W2890148417 hasAuthorship W2890148417A5078163062 @default.
- W2890148417 hasConcept C121608353 @default.
- W2890148417 hasConcept C126322002 @default.
- W2890148417 hasConcept C203014093 @default.
- W2890148417 hasConcept C2776107976 @default.
- W2890148417 hasConcept C502942594 @default.
- W2890148417 hasConcept C71924100 @default.
- W2890148417 hasConcept C8891405 @default.
- W2890148417 hasConceptScore W2890148417C121608353 @default.
- W2890148417 hasConceptScore W2890148417C126322002 @default.
- W2890148417 hasConceptScore W2890148417C203014093 @default.
- W2890148417 hasConceptScore W2890148417C2776107976 @default.
- W2890148417 hasConceptScore W2890148417C502942594 @default.
- W2890148417 hasConceptScore W2890148417C71924100 @default.
- W2890148417 hasConceptScore W2890148417C8891405 @default.
- W2890148417 hasIssue "15_suppl" @default.
- W2890148417 hasLocation W28901484171 @default.
- W2890148417 hasOpenAccess W2890148417 @default.
- W2890148417 hasPrimaryLocation W28901484171 @default.
- W2890148417 hasRelatedWork W1971992579 @default.
- W2890148417 hasRelatedWork W2091020218 @default.
- W2890148417 hasRelatedWork W2418638721 @default.
- W2890148417 hasRelatedWork W2771066073 @default.
- W2890148417 hasRelatedWork W3030649553 @default.
- W2890148417 hasRelatedWork W3189892794 @default.
- W2890148417 hasRelatedWork W3214265212 @default.
- W2890148417 hasRelatedWork W4286629873 @default.
- W2890148417 hasRelatedWork W4291367166 @default.
- W2890148417 hasRelatedWork W4321368025 @default.
- W2890148417 hasVolume "36" @default.
- W2890148417 isParatext "false" @default.
- W2890148417 isRetracted "false" @default.
- W2890148417 magId "2890148417" @default.
- W2890148417 workType "article" @default.